Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases

ESVS Guidelines Committee; Document Reviewers

doi:https://doi.org/10.1016/j.ejvs.2023.03.042

Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases

ESVS Guidelines Committee, Document Reviewers

Research output: Contribution to journal › Article › Academic › peer-review

48 Citations (Scopus)

Original language	English
Pages (from-to)	627-689
Number of pages	63
Journal	European Journal of Vascular and Endovascular Surgery
Volume	65
Issue number	5
Early online date	2023
DOIs	https://doi.org/10.1016/j.ejvs.2023.03.042
Publication status	Published - May 2023

Access to Document

https://doi.org/10.1016/j.ejvs.2023.03.042

Cite this

@article{8fe31ffefb7e47808b922d168bf7797a,

title = "Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases",

author = "Twine, {Christopher P.} and Kakkos, {Stavros K.} and Victor Aboyans and Iris Baumgartner and Christian-Alexander Behrendt and Sergi Bellmunt-Montoya and Bernd Jilma and Joakim Nordanstig and Athanasios Saratzis and Reekers, {Jim A.} and Petar Zlatanovic and {ESVS Guidelines Committee} and Antoniou, {George A.} and {de Borst}, {Gert J.} and {Bastos Gon{\c c}alves}, Frederico and Nabil Chakf{\'e} and Raphael Coscas and Dias, {Nuno V.} and Hinchliffe, {Robert J.} and Phillipe Kolh and Lindholt, {Jes S.} and Mees, {Barend M. E.} and Resch, {Timothy A.} and Santi Trimarchi and Riikka Tulamo and Vermassen, {Frank E. G.} and Anders Wanhainen and {Document Reviewers} and Igor Koncar and Robert Fitridge and Miltos Matsagkas and Marco Valgimigli",

note = "Funding Information: The authors would like to thank: Mr Graeme Ambler, Consultant vascular surgeon at Addenbrooke's Hospital Cambridge, for performing a network meta-analysis comparing clopidogrel with aspirin and rivaroxaban for patients with stable PAD for this guideline. 186 Professor Byung-Boong Lee, Centre for the Lymphoedema and Vascular Malformations, George Washington University, Washington, DC, USA, for advice for section 6 Congenital vascular malformation. Dr Dominick McCabe, member of the ESVS carotid guideline writing committee Trinity College, Dublin, for text from the updated ESVS carotid guideline which helped harmonise recommendations in 4.1 Atherosclerotic carotid artery disease and 4.2 Atherosclerotic vertebral artery disease. Professor Stephan Moll, Professor of Medicine at UNC School of Medicine, for consenting to the reproduction of a table for section 4.11.4 Thrombophilia (publisher permission also obtained). 277 Professor Ross Naylor, chair of the ESVS carotid guidelines, for help harmonising sections 4.1 Atherosclerotic carotid artery disease and 4.2 Atherosclerotic vertebral artery disease with the updated ESVS carotid guideline, which was developed in parallel with this guideline. Dr Marlene Stewart, managing editor of Cochrane Vascular for co-ordinating the update of the Cochrane Review “Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts”. 36 Dr Kitty Wong, foundation doctor at North Bristol NHS trust, for performing two meta-analyses for this guideline in association with Dr Petar Zlatanovic. Funding Information: Members of the Guideline Writing Committee (GWC) were selected by the guideline chairs and ESVS Guideline Steering Committee to represent clinician groups involved in antithrombotic therapy decision making for patients with vascular disease. This included representation from the disciplines of angiology, phlebology, cardiology, clinical pharmacology, interventional radiology, vascular medicine, and vascular surgery ( Appendix A ). Members of the GWC have provided disclosure statements regarding relationships that might be perceived as conflicts of interest. These are available from ESVS headquarters ( [email protected] ). Members of the GWC received no financial support from any pharmaceutical, device, or industry body to develop these guidelines. Videoconference software support was funded by the ESVS. The ESVS Guideline Steering Committee was responsible for undertaking the review process and reviewed the document at each round. The final version was checked and approved by the GWC and ESVS Guideline Steering Committee.",

year = "2023",

month = may,

doi = "https://doi.org/10.1016/j.ejvs.2023.03.042",

language = "English",

volume = "65",

pages = "627--689",

journal = "European Journal of Vascular and Endovascular Surgery",

issn = "1078-5884",

publisher = "W.B. Saunders Ltd",

number = "5",

}

Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. / ESVS Guidelines Committee; Document Reviewers.
In: European Journal of Vascular and Endovascular Surgery, Vol. 65, No. 5, 05.2023, p. 627-689.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases

AU - Twine, Christopher P.

AU - Kakkos, Stavros K.

AU - Aboyans, Victor

AU - Baumgartner, Iris

AU - Behrendt, Christian-Alexander

AU - Bellmunt-Montoya, Sergi

AU - Jilma, Bernd

AU - Nordanstig, Joakim

AU - Saratzis, Athanasios

AU - Reekers, Jim A.

AU - Zlatanovic, Petar

AU - ESVS Guidelines Committee

AU - Antoniou, George A.

AU - de Borst, Gert J.

AU - Bastos Gonçalves, Frederico

AU - Chakfé, Nabil

AU - Coscas, Raphael

AU - Dias, Nuno V.

AU - Hinchliffe, Robert J.

AU - Kolh, Phillipe

AU - Lindholt, Jes S.

AU - Mees, Barend M. E.

AU - Resch, Timothy A.

AU - Trimarchi, Santi

AU - Tulamo, Riikka

AU - Vermassen, Frank E. G.

AU - Wanhainen, Anders

AU - Document Reviewers

AU - Koncar, Igor

AU - Fitridge, Robert

AU - Matsagkas, Miltos

AU - Valgimigli, Marco

N1 - Funding Information: The authors would like to thank: Mr Graeme Ambler, Consultant vascular surgeon at Addenbrooke's Hospital Cambridge, for performing a network meta-analysis comparing clopidogrel with aspirin and rivaroxaban for patients with stable PAD for this guideline. 186 Professor Byung-Boong Lee, Centre for the Lymphoedema and Vascular Malformations, George Washington University, Washington, DC, USA, for advice for section 6 Congenital vascular malformation. Dr Dominick McCabe, member of the ESVS carotid guideline writing committee Trinity College, Dublin, for text from the updated ESVS carotid guideline which helped harmonise recommendations in 4.1 Atherosclerotic carotid artery disease and 4.2 Atherosclerotic vertebral artery disease. Professor Stephan Moll, Professor of Medicine at UNC School of Medicine, for consenting to the reproduction of a table for section 4.11.4 Thrombophilia (publisher permission also obtained). 277 Professor Ross Naylor, chair of the ESVS carotid guidelines, for help harmonising sections 4.1 Atherosclerotic carotid artery disease and 4.2 Atherosclerotic vertebral artery disease with the updated ESVS carotid guideline, which was developed in parallel with this guideline. Dr Marlene Stewart, managing editor of Cochrane Vascular for co-ordinating the update of the Cochrane Review “Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts”. 36 Dr Kitty Wong, foundation doctor at North Bristol NHS trust, for performing two meta-analyses for this guideline in association with Dr Petar Zlatanovic. Funding Information: Members of the Guideline Writing Committee (GWC) were selected by the guideline chairs and ESVS Guideline Steering Committee to represent clinician groups involved in antithrombotic therapy decision making for patients with vascular disease. This included representation from the disciplines of angiology, phlebology, cardiology, clinical pharmacology, interventional radiology, vascular medicine, and vascular surgery ( Appendix A ). Members of the GWC have provided disclosure statements regarding relationships that might be perceived as conflicts of interest. These are available from ESVS headquarters ( [email protected] ). Members of the GWC received no financial support from any pharmaceutical, device, or industry body to develop these guidelines. Videoconference software support was funded by the ESVS. The ESVS Guideline Steering Committee was responsible for undertaking the review process and reviewed the document at each round. The final version was checked and approved by the GWC and ESVS Guideline Steering Committee.

PY - 2023/5

Y1 - 2023/5

UR - http://www.scopus.com/inward/record.url?scp=85157969565&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.ejvs.2023.03.042

DO - https://doi.org/10.1016/j.ejvs.2023.03.042

M3 - Article

C2 - 37019274

SN - 1078-5884

VL - 65

SP - 627

EP - 689

JO - European Journal of Vascular and Endovascular Surgery

JF - European Journal of Vascular and Endovascular Surgery

IS - 5

ER -

Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases

Access to Document

Other files and links

Cite this